Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 18;19(10):3226. doi: 10.3390/ijms19103226

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Loss of cardioprotective effect mediated by TRPV-1 and increase in infarct size with intraperitoneal injection of TRPV-1-inhibitor (Capsazepine), Infarct size expressed in (%). Comparing the 2 groups, Control (Saline) + DMSO (Control (Saline) + Dimethyl sulfoxide (i.p), n = 7) and Sitg (50 mg) + DMSO (Sitagliptin 50 mg + Dimethyl sulfoxide (i.p), n = 6), shows a significant decrease in infarct size (* p < 0.05), while this protective effect was abolished comparing the Sitg (50 mg) + CAP (Sitagliptin 50 mg + Capsazepine (i.p), n = 8) group with the Sitg (50 mg) + DMSO treated group (# p < 0.05), which means that cardioprotective effect of Sitagliptin against infarction is mediated by TRPV-1. A significant difference (†† p < 0.01) was observed in Sitg (50 mg) + DMSO (Sitagliptin (50 mg) + Dimethyl sulfoxide (i.p), n = 6) group, compared to Saline + CAP (Saline + Capsazepine (i.p), n = 8). Data plotted as (Mean ± SEM).